The Department of Veterans Affairs has launched a randomized clinical trial testing whether semaglutide, the GLP-1 medication sold as Ozempic and Wegovy, can reduce drinking among veterans with alcohol use disorder. Recruitment began at the end of July across 18 VA medical centers.
The study, called the Cessation or Reduction of Alcohol Consumption in Veterans trial, or CRAVE, will enroll more than 600 veterans aged 18 to 80 with moderate or severe alcohol use disorder. Participants will receive weekly injections of either semaglutide or a placebo for 24 weeks, followed by a safety follow-up period, and researchers will track changes in drinking, overall health, and quality of life.
The most important thing for readers to understand is what this announcement is not. It is not a new treatment, not an approved use, and not a result. Semaglutide is approved by the FDA for type 2 diabetes and chronic weight management, not for alcohol use disorder. The VA has been explicit that it discourages self-medicating or substituting a GLP-1 for established treatments.
The Design Is What Makes This Study Different
Interest in GLP-1 medications and drinking has been driven largely by observational data. The VA announcement cites an earlier analysis that examined records of VA patients with diabetes and found lower rates of alcohol use disorder and other substance use disorders among those taking GLP-1 medications compared with similar patients on other diabetes drugs.
That kind of finding is a starting point, not proof. People prescribed GLP-1 medications differ from those who are not in ways that are difficult to fully adjust for, including engagement with care, motivation and underlying health. Observational data can show an association without establishing that the drug caused the reduction in drinking.
A randomized, double-blind, placebo-controlled trial addresses that problem by assigning treatment at random and concealing who receives which. According to its registration on ClinicalTrials.gov, the study is a multicenter trial sponsored by the VA Office of Research and Development, with eligibility based on DSM-5 criteria for moderate to severe alcohol use disorder among treatment-seeking veterans.
Researchers believe semaglutide may act on brain circuits involved in reward processing, which is the biological rationale for expecting an effect on drinking as well as eating.
The Numbers Behind the Research Priority
More than 400,000 veterans in the VA health system carry a diagnosis of alcohol use disorder, and the department notes that some estimates put the condition at nearly 11 percent of U.S. adults.
That gap between how common the condition is and how few people receive medication for it is the core problem. Only three medications are FDA-approved for alcohol use disorder, and they are prescribed to a small fraction of people who could benefit. A genuinely new option would matter, which is precisely why the evidence needs to be strong before anyone acts on it.
VA Secretary Doug Collins said "this clinical trial reflects medical research that VA is uniquely situated to launch,"adding that exploring emerging options aims to expand the tools available to help veterans manage their health and recovery.
The 18 participating sites span 13 states. Veterans interested in participating should contact their local VA medical center rather than seeking the drug elsewhere; the Minneapolis VA and other participating facilities have announced their involvement individually.
Reading the Evidence Without Getting Ahead of It
This is a well-designed trial, and its structure is why it is worth taking seriously. It is also years from an answer. Registration records list estimated primary completion in 2028 and full completion in 2029, so efficacy results will not be available for a considerable time.
Several limitations are worth naming now. The population is veterans, who differ from the general adult population in age distribution, sex balance, and co-occurring conditions, so results may not transfer cleanly. The treatment period is 24 weeks, which will not answer whether any benefit persists after the medication stops. Participants are treatment-seeking, meaning they are already motivated to change, and outcomes in that group often differ from outcomes in people who are not. And semaglutide carries known side effects including nausea, vomiting, and diarrhea, with additional safety questions in people who drink heavily.
Nothing about current medical guidance changes as a result of this launch. Naltrexone, acamprosate and disulfiram remain the approved medications, and behavioral treatment remains a core part of care.
What Veterans and Families Should Do Right Now
Anyone struggling with alcohol should not wait years for this trial. Effective treatment exists today, and the VA has said evidence-based options are available at its facilities.
Do not obtain semaglutide from unverified online sellers or compounding sources in the hope of reducing drinking. Products from unregulated sellers have been linked to dosing errors and contamination, and using a GLP-1 in place of established treatment carries real risk, particularly for anyone who may experience withdrawal. Alcohol withdrawal can be medically dangerous and sometimes requires supervised care, so stopping abruptly without guidance is not advisable.
Veterans can ask their VA primary care team or a mental health provider about medication options and counseling. Non-veterans can reach the SAMHSA National Helpline at 1-800-662-4357, which is free, confidential, and available around the clock. Veterans in crisis can reach the Veterans Crisis Line by dialing 988 and pressing 1.
Watch for interim safety reporting and, eventually, published results. Reporting by Military Times and other outlets will track enrollment progress. MedicalDaily will report the findings when they are published, and will not treat preliminary or conference data as a conclusion.
Alcohol use disorder is a treatable medical condition, and this topic can be difficult. If you or someone close to you is struggling, help is available now.
Frequently Asked Questions
Is semaglutide approved to treat alcohol use disorder? No. It is approved for type 2 diabetes and chronic weight management. Its use for alcohol use disorder is investigational.
How large is the trial and who can join? More than 600 veterans aged 18 to 80 with moderate or severe alcohol use disorder, enrolling at 18 VA medical centers. Veterans should contact their local VA facility to ask about participation.
When will results be available? Registration records estimate primary completion in 2028, with full completion in 2029. No efficacy results exist now.
What did earlier research show? Observational analyses of health records found lower rates of alcohol and substance use disorders among patients taking GLP-1 medications, but those studies show association rather than cause.
Why does a randomized trial matter more? Random assignment and blinding reduce the chance that differences between groups, rather than the drug itself, explain the result.
Should I try a GLP-1 to cut back on drinking? No. Talk to a clinician instead. Approved medications and behavioral treatments exist, and stopping alcohol abruptly can be medically dangerous without supervision.
Where can someone get help today? The SAMHSA National Helpline is 1-800-662-4357. Veterans in crisis can dial 988 and press 1. Veterans can also ask their VA care team about treatment options.
